1)草野元康,前田正毅,下山康之,他.食道運動機能とアカラシア関連疾患.日消誌 100:1095-1105, 2003
2)Hirano T, Yamada M, Igusa R, et al. Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer:a case report and literature review. Respir Investig 54:211-215, 2016
3)Babaei A, Szabo A, Shad S, et al. Chronic daily opioid exposure is associated with dysphagia, esophageal outflow obstruction, and disordered peristalsis. Neurogastroenterol Motil 31:e13601, 2019
4)Roberts CG, Hummers LK, Ravich WJ, et al. A case-control study of the pathology of oesophageal disease in systemic sclerosis(scleroderma). Gut 55:1697-1703, 2006
5)Kuribayashi S, Matsumura N, Sohda M, et al. Risk of perforation during endoscopic resection of esophageal lesions in patients with systemic sclerosis. Gastrointest Endosc 91:441-442, 2020
6)松崎勉,杉山雅,西岡利夫,他.進行性全身性硬化症の夜間食道胃運動と逆流性食道炎発症に関する研究—第一報.日消誌 80:2329-2338, 1983
7)松崎勉,杉山雅,西岡利夫,他.進行性全身性硬化症の逆流性食道炎発症に関する研究(第2報)—夜間食道胃運動と食道内pH.日消誌 82:1300-1307, 1985
8)Roman S, Hot A, Fabien N, et al. Esophageal dysmotility associated with systemic sclerosis:a high-resolution manometry study. Dis Esophagus 24:299-304, 2011
9)Kuribayashi S, Motegi SI, Hara K, et al. Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis. J Gastroenterol 54:950-962, 2019
10)Carlson DA, Crowell MD, Kimmel JN, et al. Loss of peristaltic reserve, determined by multiple rapid swallows, is the most frequent esophageal motility abnormality in patients with systemic sclerosis. Clin Gastroenterol Hepatol 14:1502-1506, 2016
11)Carlson DA, Prescott JE, Germond E, et al. Heterogeneity of primary and secondary peristalsis in systemic sclerosis:A new model of “scleroderma esophagus”. Neurogastroenterol Motil 34:e14284, 2022
12)Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil 28:1157-1165, 2016
13)Stern EK, Carlson DA, Falmagne S, et al. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil 30:10.1111/nmo.13247, 2018
14)Tabuchi M, Minami H, Akazawa Y, et al. Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease. Biomed Rep 14:25, 2021
15)Shirai Y, Kawami N, Iwakiri K, et al. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. J Scleroderma Relat Disord 7:57-61, 2022
16)Kuribayashi S, Nakamura F, Motegi SI, et al. Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan. J Gastroenterol 59:179-186, 2024
17)Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma:a study using pH-impedance monitoring. Am J Respir Crit Care Med 179:408-413, 2009
18)O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology 154:333-345, 2018
19)Roman S, Hirano I, Kwiatek MA, et al. Manometric features of eosinophilic esophagitis in esophageal pressure topography. Neurogastroenterol Motil 23:208-214, e111, 2011
20)Sato H, Takeuchi M, Takahashi K. Eosinophilic infiltration of the muscularis propria in a patient with jackhammer esophagus treated with per-oral endoscopic myotomy. Clin Gastroenterol Hepatol 13:e33-34, 2015
21)Kwiatek MA, Hirano I, Kahrilas PJ, et al. Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology 140:82-90, 2011
22)Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis:validation of a novel classification and grading system. Gut 62:489-495, 2013
23)Savarino E, Gemignani L, Zentilin P, et al. Achalasia with dense eosinophilic infiltrate responds to steroid therapy. Clin Gastroenterol Hepatol 9:1104-1106, 2011